TY - JOUR
T1 - The 2015 World Health Organization Classification of Lung Tumors
T2 - Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification
AU - On Behalf of the WHO Panel
AU - Travis, William D.
AU - Brambilla, Elisabeth
AU - Nicholson, Andrew G.
AU - Yatabe, Yasushi
AU - Austin, John H.M.
AU - Beasley, Mary Beth
AU - Chirieac, Lucian R.
AU - Dacic, Sanja
AU - Duhig, Edwina
AU - Flieder, Douglas B.
AU - Geisinger, Kim
AU - Hirsch, Fred R.
AU - Ishikawa, Yuichi
AU - Kerr, Keith M.
AU - Noguchi, Masayuki
AU - Pelosi, Giuseppe
AU - Powell, Charles A.
AU - Tsao, Ming Sound
AU - Wistuba, Ignacio
N1 - Publisher Copyright:
Copyright © 2015 by the International Association for the Study of Lung Cancer.
PY - 2015/9/26
Y1 - 2015/9/26
N2 - The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. The most significant changes in this edition involve (1) use of immunohistochemistry throughout the classification, (2) a new emphasis on genetic studies, in particular, integration of molecular testing to help personalize treatment strategies for advanced lung cancer patients, (3) a new classification for small biopsies and cytology similar to that proposed in the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (4) a completely different approach to lung adenocarcinoma as proposed by the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (5) restricting the diagnosis of large cell carcinoma only to resected tumors that lack any clear morphologic or immunohistochemical differentiation with reclassification of the remaining former large cell carcinoma subtypes into different categories, (6) reclassifying squamous cell carcinomas into keratinizing, nonkeratinizing, and basaloid subtypes with the nonkeratinizing tumors requiring immunohistochemistry proof of squamous differentiation, (7) grouping of neuroendocrine tumors together in one category, (8) adding NUT carcinoma, (9) changing the term sclerosing hemangioma to sclerosing pneumocytoma, (10) changing the name hamartoma to "pulmonary hamartoma," (11) creating a group of PEComatous tumors that include (a) lymphangioleiomyomatosis, (b) PEComa, benign (with clear cell tumor as a variant) and (c) PEComa, malignant, (12) introducing the entity pulmonary myxoid sarcoma with an EWSR1-CREB1 translocation, (13) adding the entities myoepithelioma and myoepithelial carcinomas, which can show EWSR1 gene rearrangements, (14) recognition of usefulness of WWTR1-CAMTA1 fusions in diagnosis of epithelioid hemangioendotheliomas, (15) adding Erdheim-Chester disease to the lymphoproliferative tumor, and (16) a group of tumors of ectopic origin to include germ cell tumors, intrapulmonary thymoma, melanoma and meningioma.
AB - The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. The most significant changes in this edition involve (1) use of immunohistochemistry throughout the classification, (2) a new emphasis on genetic studies, in particular, integration of molecular testing to help personalize treatment strategies for advanced lung cancer patients, (3) a new classification for small biopsies and cytology similar to that proposed in the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (4) a completely different approach to lung adenocarcinoma as proposed by the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (5) restricting the diagnosis of large cell carcinoma only to resected tumors that lack any clear morphologic or immunohistochemical differentiation with reclassification of the remaining former large cell carcinoma subtypes into different categories, (6) reclassifying squamous cell carcinomas into keratinizing, nonkeratinizing, and basaloid subtypes with the nonkeratinizing tumors requiring immunohistochemistry proof of squamous differentiation, (7) grouping of neuroendocrine tumors together in one category, (8) adding NUT carcinoma, (9) changing the term sclerosing hemangioma to sclerosing pneumocytoma, (10) changing the name hamartoma to "pulmonary hamartoma," (11) creating a group of PEComatous tumors that include (a) lymphangioleiomyomatosis, (b) PEComa, benign (with clear cell tumor as a variant) and (c) PEComa, malignant, (12) introducing the entity pulmonary myxoid sarcoma with an EWSR1-CREB1 translocation, (13) adding the entities myoepithelioma and myoepithelial carcinomas, which can show EWSR1 gene rearrangements, (14) recognition of usefulness of WWTR1-CAMTA1 fusions in diagnosis of epithelioid hemangioendotheliomas, (15) adding Erdheim-Chester disease to the lymphoproliferative tumor, and (16) a group of tumors of ectopic origin to include germ cell tumors, intrapulmonary thymoma, melanoma and meningioma.
KW - Carcinoid
KW - Large cell carcinoma
KW - Lung adenocarcinoma
KW - Lung cancer
KW - Lung tumors
KW - Small cell carcinoma
KW - Squamous cell carcinoma
KW - WHO classification
UR - http://www.scopus.com/inward/record.url?scp=84940100919&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000630
DO - 10.1097/JTO.0000000000000630
M3 - Review article
C2 - 26291008
AN - SCOPUS:84940100919
SN - 1556-0864
VL - 10
SP - 1243
EP - 1260
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 9
ER -